The BPC-157 case study in the previous lesson illustrates a pattern that shows up across regulatory processes generally, not just for peptides: an advisory committee’s recommendation is a data point FDA weighs, not a rule that takes effect on its own. Formal rulemaking — the process that actually changes a substance’s legal status — involves its own steps, timelines, and opportunities for public comment, and realistically takes months to years even after a favorable advisory vote. That gap between “recommended” and “enacted” is exactly where a lot of confusion and outdated claims tend to come from.

This is the same evidence-literacy habit covered in Research & Mechanisms, applied to regulatory information instead of scientific findings: check the source, check the date, and understand what tier of authority you’re actually looking at. A PCAC recommendation is a meaningful signal, much like a single study is meaningful evidence — but neither one is the final word by itself. Treating regulatory status as a snapshot in time, and checking it directly when it matters, is the more reliable habit than assuming last year’s summary still holds.